Clinical Trials Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2020; 26(46): 7405-7415
Published online Dec 14, 2020. doi: 10.3748/wjg.v26.i46.7405
Effect of postoperative early enteral nutrition on clinical outcomes and immune function of cholangiocarcinoma patients with malignant obstructive jaundice
Bing-Qiang Ma, Shi-Yong Chen, Ze-Bin Jiang, Biao Wu, Yu He, Xin-Xin Wang, Yuan Li, Peng Gao, Xiao-Jun Yang
Bing-Qiang Ma, Ze-Bin Jiang, Peng Gao, Xiao-Jun Yang, Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China
Shi-Yong Chen, Biao Wu, Yuan Li, School of Clinical Medicine, Ningxia Medical University, Yinchuan 750000, Ningxia Hui Autonomous Region, China
Yu He, Xin-Xin Wang, School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China
Author contributions: Ma BQ, Chen SY, and Jiang ZB contributed equally to this work and should be considered as co-first authors; Ma BQ, Chen SY, Jiang ZB, and Yang XJ conceived the experiment; Ma BQ and Jiang ZB analyzed the results; Ma BQ and Chen SY wrote the original draft; Ma BQ, Chen SY, Jiang ZB, Wu B, He Y, Wang XX, Li Y, Gao P, and Yang XJ conducted the experiment; All the authors revised the manuscript and approved the final version.
Supported by National Natural Science Foundation of China, No. 81660398; and The Hospital Key Program of National Scientific Research Cultivation Plan, No. 19SYPYA-12.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Gansu Provincial Hospital (Approval No. 2016-036).
Clinical trial registration statement: This study was registered at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx). The registration identification number is ChiCTR2000034561.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Jun Yang, MD, PhD, Chief Doctor, Professor, Surgeon, Department of General Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com
Received: August 27, 2020
Peer-review started: August 27, 2020
First decision: November 3, 2020
Revised: November 15, 2020
Accepted: November 21, 2020
Article in press: November 21, 2020
Published online: December 14, 2020
Processing time: 108 Days and 15.5 Hours
Core Tip

Core Tip: The aim of this prospective clinical trial was to investigate the effects of postoperative early enteral nutrition (EEN) on immunity function and clinical outcomes of cholangiocarcinoma patients with malignant obstructive jaundice (MOJ). Patients were randomly divided into the early enteral nutrition and parenteral nutrition (EEN+PN) and total parenteral nutrition (TPN) groups. As a result, the CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T cell counts, and the immunoglobulin (Ig) G, IgM, and IgA levels in the EEN+PN group were significantly higher than those in the TPNgroup on postoperative days 3 and 7 (P < 0.05). A postoperative EEN program could improve the clinical outcomes and immune functions of cholangiocarcinoma patients with MOJ and is thus beneficial to patient recovery.